Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
CANF Quote, Financials, Valuation and Earnings
Last price:
$4.38
Seasonality move
:
-19.93%
Day range:
$4.28 - $4.44
52-week range:
$3.36 - $46.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
24.77x
P/B ratio:
0.93x
Volume:
11.9K
Avg. volume:
69.9K
1-year change:
-86.13%
Market cap:
$5.8M
Revenue:
$677.2K
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
BLRX
BioLineRx Ltd.
|
$492K | -$0.77 | -95.85% | -49.07% | $20.33 |
|
CGEN
Compugen Ltd.
|
$14.3M | $0.14 | -63.51% | -2.83% | $5.80 |
|
EVGN
Evogene Ltd.
|
$275K | -$0.26 | -82.93% | -68.8% | $2.50 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
$4.44 | $2.50 | $5.8M | -- | $0.00 | 0% | 24.77x |
|
BLRX
BioLineRx Ltd.
|
$2.82 | $20.33 | $12.3M | -- | $0.00 | 0% | 0.78x |
|
CGEN
Compugen Ltd.
|
$1.79 | $5.80 | $167.4M | 55.83x | $0.00 | 0% | 23.92x |
|
EVGN
Evogene Ltd.
|
$0.89 | $2.50 | $7.7M | -- | $0.00 | 0% | 1.25x |
|
PLUR
Pluri, Inc.
|
$3.68 | $12.00 | $37M | -- | $0.00 | 0% | 22.48x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$0.89 | -- | $7.8M | -- | $0.00 | 0% | 15.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.875 | -- | -- |
|
BLRX
BioLineRx Ltd.
|
36.81% | 2.493 | 69.17% | 1.84x |
|
CGEN
Compugen Ltd.
|
6.3% | 2.410 | 2.14% | 4.24x |
|
EVGN
Evogene Ltd.
|
68.82% | 1.695 | 9.67% | 4.01x |
|
PLUR
Pluri, Inc.
|
172.93% | 0.066 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.265 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
BLRX
BioLineRx Ltd.
|
$225K | -$2.2M | -9.37% | -18.74% | -516.85% | -$2.1M |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
EVGN
Evogene Ltd.
|
-$126K | -$2.7M | -57.78% | -66.95% | -870.19% | -$3.8M |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
Can-Fite BioPharma Ltd. vs. Competitors
-
Which has Higher Returns CANF or BLRX?
BioLineRx Ltd. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -228.81%. Can-Fite BioPharma Ltd.'s return on equity of -- beat BioLineRx Ltd.'s return on equity of -18.74%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M -
What do Analysts Say About CANF or BLRX?
Can-Fite BioPharma Ltd. has a consensus price target of $2.50, signalling upside risk potential of 1026.13%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 621.04%. Given that Can-Fite BioPharma Ltd. has higher upside potential than BioLineRx Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than BioLineRx Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.1 1 0 BLRXBioLineRx Ltd.2 0 0 -
Is CANF or BLRX More Risky?
Can-Fite BioPharma Ltd. has a beta of 1.068, which suggesting that the stock is 6.818% more volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.321, suggesting its more volatile than the S&P 500 by 32.082%.
-
Which is a Better Dividend Stock CANF or BLRX?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or BLRX?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than BioLineRx Ltd. quarterly revenues of $429K. Can-Fite BioPharma Ltd.'s net income of -- is lower than BioLineRx Ltd.'s net income of -$981.6K. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 24.77x versus 0.78x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.24.77x -- -- -- BLRXBioLineRx Ltd.0.78x -- $429K -$981.6K
-
Which has Higher Returns CANF or CGEN?
Compugen Ltd. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -369.06%. Can-Fite BioPharma Ltd.'s return on equity of -- beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About CANF or CGEN?
Can-Fite BioPharma Ltd. has a consensus price target of $2.50, signalling upside risk potential of 1026.13%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 224.02%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Compugen Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.1 1 0 CGENCompugen Ltd.5 0 0 -
Is CANF or CGEN More Risky?
Can-Fite BioPharma Ltd. has a beta of 1.068, which suggesting that the stock is 6.818% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.864, suggesting its more volatile than the S&P 500 by 186.386%.
-
Which is a Better Dividend Stock CANF or CGEN?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or CGEN?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Can-Fite BioPharma Ltd.'s net income of -- is lower than Compugen Ltd.'s net income of -$7M. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 24.77x versus 23.92x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.24.77x -- -- -- CGENCompugen Ltd.23.92x 55.83x $1.9M -$7M
-
Which has Higher Returns CANF or EVGN?
Evogene Ltd. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -874.68%. Can-Fite BioPharma Ltd.'s return on equity of -- beat Evogene Ltd.'s return on equity of -66.95%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- EVGNEvogene Ltd.-40.39% $0.44 $19.8M -
What do Analysts Say About CANF or EVGN?
Can-Fite BioPharma Ltd. has a consensus price target of $2.50, signalling upside risk potential of 1026.13%. On the other hand Evogene Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 181.66%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Evogene Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Evogene Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.1 1 0 EVGNEvogene Ltd.1 0 0 -
Is CANF or EVGN More Risky?
Can-Fite BioPharma Ltd. has a beta of 1.068, which suggesting that the stock is 6.818% more volatile than S&P 500. In comparison Evogene Ltd. has a beta of 1.352, suggesting its more volatile than the S&P 500 by 35.162%.
-
Which is a Better Dividend Stock CANF or EVGN?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evogene Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. Evogene Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or EVGN?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than Evogene Ltd. quarterly revenues of $312K. Can-Fite BioPharma Ltd.'s net income of -- is lower than Evogene Ltd.'s net income of -$2.7M. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while Evogene Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 24.77x versus 1.25x for Evogene Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.24.77x -- -- -- EVGNEvogene Ltd.1.25x -- $312K -$2.7M
-
Which has Higher Returns CANF or PLUR?
Pluri, Inc. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -3470.71%. Can-Fite BioPharma Ltd.'s return on equity of -- beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About CANF or PLUR?
Can-Fite BioPharma Ltd. has a consensus price target of $2.50, signalling upside risk potential of 1026.13%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 226.09%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Pluri, Inc., analysts believe Can-Fite BioPharma Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.1 1 0 PLURPluri, Inc.1 0 0 -
Is CANF or PLUR More Risky?
Can-Fite BioPharma Ltd. has a beta of 1.068, which suggesting that the stock is 6.818% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.181%.
-
Which is a Better Dividend Stock CANF or PLUR?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or PLUR?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $198K. Can-Fite BioPharma Ltd.'s net income of -- is lower than Pluri, Inc.'s net income of -$6.9M. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 24.77x versus 22.48x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.24.77x -- -- -- PLURPluri, Inc.22.48x -- $198K -$6.9M
-
Which has Higher Returns CANF or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -- compared to Can-Fite BioPharma Ltd.'s net margin of -341.36%. Can-Fite BioPharma Ltd.'s return on equity of -- beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital CANFCan-Fite BioPharma Ltd.-- -- -- XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About CANF or XTLB?
Can-Fite BioPharma Ltd. has a consensus price target of $2.50, signalling upside risk potential of 1026.13%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 3273.44%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CANFCan-Fite BioPharma Ltd.1 1 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is CANF or XTLB More Risky?
Can-Fite BioPharma Ltd. has a beta of 1.068, which suggesting that the stock is 6.818% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.178, suggesting its more volatile than the S&P 500 by 17.838%.
-
Which is a Better Dividend Stock CANF or XTLB?
Can-Fite BioPharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Can-Fite BioPharma Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CANF or XTLB?
Can-Fite BioPharma Ltd. quarterly revenues are --, which are smaller than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. Can-Fite BioPharma Ltd.'s net income of -- is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, Can-Fite BioPharma Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Can-Fite BioPharma Ltd. is 24.77x versus 15.82x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CANFCan-Fite BioPharma Ltd.24.77x -- -- -- XTLBXTL Biopharmaceuticals Ltd.15.82x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
